Results 81 to 90 of about 285,238 (370)

Prevalence of Infectious Diseases Among 6078 Individuals With Down Syndrome in the United States

open access: yesJournal of Patient-Centered Research and Reviews, 2022
A recent disease prevalence study of the largest documented Down syndrome (DS) cohort in the United States strongly suggested significant disparity in general infectious disease conditions among individuals with DS versus those without DS. In this follow-
Veronica Fitzpatrick   +6 more
doaj   +1 more source

Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study

open access: yesEuropean Respiratory Journal, 2017
We studied the prevalence, burden and potential risk factors for chronic bronchitis symptoms in the Burden of Obstructive Lung Disease study. Representative population-based samples of adults aged ≥40 years were selected in participating sites ...
F. Mejza   +8 more
semanticscholar   +1 more source

Single‐Cell Sequencing‐Guided Annotation of Rare Tumor Cells for Deep Learning‐Based Cytopathologic Diagnosis of Early Lung Cancer

open access: yesAdvanced Science, EarlyView.
This study presents an innovative method to generate high‐quality, objectively annotated cytology datasets without relying on expert involvement. Large‐scale single‐cell DNA sequencing is used as an objective ground truth of cell annotation for generating an accurate, unbiased dataset of exfoliated tumor cells from bronchoalveolar lavage cytology ...
Yichun Zhao   +10 more
wiley   +1 more source

Virucidal Efficacy of Laser-Generated Copper Nanoparticle Coatings Against Model Coronavirus and Herpesvirus [PDF]

open access: yesarXiv, 2023
High-efficiency antiviral surfaces can be effective means to fight against viral diseases such as the recent Covid-19 pandemic. Copper and copper oxides, as well as their nanoparticles (Cu NPs) and coatings, are among the effective antiviral materials having internal and external biocidal effects on viruses.
arxiv  

Penatalaksanaan Fisioterapi Pada Kasus Bronkitis Akut Di Rs Muhamaadiyah Yogyakarta [PDF]

open access: yes, 2015
Background: Bronchitis is one of the top conditions that encourage patients to seek medical care. It is characterized by inflammation of the bronchial tract (or bronchi), air duct that runs from the trachea into the small airways and alveoli.
, Isnaini Herawati, S.Fis.,Ftr.,M.Sc   +1 more
core  

Understanding Antibiotic Use in Minya District, Egypt: Physician and Pharmacist Prescribing and the Factors Influencing Their Practices

open access: yesAntibiotics, 2014
Overuse of antibiotics has contributed to the emergence of antibiotic-resistant bacteria globally. In Egypt, patients can purchase antibiotics without a prescription, and we hypothesized frequent inappropriate antibiotic prescribing and dispensing.
Kathleen L. Dooling   +8 more
doaj   +1 more source

Treatment and management of chronic bronchitis [PDF]

open access: yes, 1992
Today, many countries and their peoples enjoy high standards of living, yet bronchitis remains a world-wide problem. Statistics show that bronchitis is one of the most frequently diagnosed major disorder in European countries (Nairman S).
Delicata, Andre
core  

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis

open access: yesEuropean Respiratory Review, 2015
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC treatment ...
M. Cazzola   +6 more
semanticscholar   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy